The influence of lymph- and haemangiosis carcinomatosa in colorectal cancer;Die bedeutung der lymph- und hamangiosis carcinomatosa beim colorectalen carcinom

Zentralblatt fur Chirurgie

Volumn 121, Issue 6, 1996, Pages 442-449

  Schultheis, K H ^a,c   Kosicki, Chr ^a   Ruckriegel, St ^a   Meyer, W ^a   Gebhardt, Chr ^a   Kaiser, A ^b   Wunsch P ^b  

^a Klin F Abdom Thorax E   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c Klin F Allgemein Thoraxchirurgie   (Germany)

Author keywords

5 year survival; adjuvant chemotherapy; Carcinomatous lymphangiosis and hemangiosis; colorectal cancer; prognosis

Indexed keywords

ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SURVIVAL TIME;

AGED; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOPLASM CIRCULATING CELLS; NEOPLASM STAGING; SURVIVAL RATE;

EID: 0030035218     PISSN: 0044409X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. AIO/ARO/CAO Konsensus zur adjuvanten Therapie bei Colon- und Rectumcarcinom vom 11. 3. 1994, Zentralbl Chir 119 (1994) 282-283.
2. Armitage NC, Robins RA, Evans DF, Turner DR, Baldwin RW, Hardcastle JD: The influence of tumor cell DNA abnormalities on survival in colorectal cancer, Br J Surg 72 (1985) 828-830.
3. Chapuis PH, Dent OF, Fisher R, Newland RC, Pheils MT, Smyth E, Coloquhoun K: A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer, Br J Surg 72 (1985) 698-702.
4. [3a] Dukes CE, Bussey HJ R: The spread of rectal cancer and its effect on prognosis, Br J Cancer 12 (1958) 309-320.
5. Gabbert HE, Meier S, Gerharz C-D, Hommel G: Neue histomorphologische Prognoseparameter beim Magencarcinom, Chirurg 63 (1992) 647-655.
6. Gall FP, Hermanek P: Wandel und derzeitiger Stand der chirurgischen Behandlung des colorektalen Carcinoms, Chirurg 63 (1992) 227-234.
7. Hermanek P jr, Wiebelt H, Riedl St, Staimmer D, Hermanek P und die Studiengruppe Kolorektales Karzinom (SGKRK): Langzeitergebnisse der chirurgischen Therapie des Coloncarcinom, Chirurg 65 (1994) 287-297.
8. Hermanek P, Hutter RVP, Sobin LH: Prognostic grouping: the next step in tumor classification, J Cancer Res Clin Oncol 116 (1990) 513-516.
9. Kraus TW, Eble MJ, Raeth U: Bisherige Entwicklung und aktueller Stand der adjuvanten Chemo- und Radiotherapie beim Kolon- und Rectumkarzinom, Langenbecks Arch Chir 379 (1994) 353-357.
10. Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmüller G: Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients, Lancet 340 (1992) 685-89.
11. Mentges B, Brückner R, Weiss C: Die Bedeutung des präoperativen CEA-Wertes für die Prognose des Rektumkarzinoms, Langenbecks Arch Chir 375 (1990) 106-111.
12. Minsky B D, Mies C: The clinical significance of vascular invasion in colorectal cancer. Dis Colon Rectum 33 (1989) 794-803.
13. Moertel Ch G, Fleming Th R, McDonald JS, Haller DG, Laurie Let al.: Levamisole and 5-Fluorouracil for adjuvant therapy of resected colon carcinoma, New Engl J of Medicine 322 (1990) 352-358.
14. NIH Consensus conference: JAMA 264/11 (1990) 1444-1450.
15. Philips RKS, Hittinger R, Blesovsky L, Fry JS, Fielding LP: Large bowel cancer: surgical pathology and 1st relationship to survival, Br J Surg 71 (1984) 604-610.
16. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichelmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J: Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma, Lancet 343 (1994) 1177-1183.
17. Schmoll H-J: Adjuvante Chemotherapie beim Rektumcarcinom. Chirurg 65 (1994) 576-584.
18. Windle R, Bell PR F, Shaw D: Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer, Br J Surg 74 (1987) 569-572.